Recursion Pharmaceuticals gives guidance on seven clinical readouts

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidance to investors, analysts, and other stakeholders during Download Day, Recursion’s investor and R&D day, on Monday, June 24, 2024. The event will feature a number of prominent speakers, including Jensen Huang, founder and CEO of NVIDIA, Deepak Nijhawan, M.D., Ph.D., UT Southwestern Distinguished Chair in Biomedical Science, and John Marioni, Ph.D., Senior VP and Head of Computational Sciences at Genentech. Updated pipeline guidance: Seven Clinical Trial Readouts expected within approximately 18 months: REC-994 Cerebral Cavernous Malformation-topline Phase 2 data readout in September 2024; REC-2282 Neurofibromatosis Type 2-preliminary Phase 2 data readout in the fourth quarter of 2024; REC-4881 Familial Adenomatous Polyposis-preliminary Phase 2 data readout in the first half of 2025; REC-4881 Advanced AXIN1/APC-Mutant Cancers-preliminary Phase 2 data readout in the first half of 2025; REC-3964 Clostridioides difficile Infection-Phase 2 study initiation in the fourth quarter of 2024 and preliminary data readout by the end of 2025; RBM39 Advanced HR-Proficient Cancers-IND submission in the third quarter of 2024, Phase 1/2 initiation in the fourth quarter of 2024 and Phase 1 dose-escalation data readout by the end of 2025; Target Epsilon-IND submission in early 2025 and Phase 1 healthy volunteer study data readout by the end of 2025. Dozens of internal and partner programs in early stages with the first LLM and causal model driven programs entering the Recursion pipeline. Partnership updates: Bayer will be the first beta-user of our LOWE LLM-orchestrated workflow software, which will be integrated across the collaboration and offer a more exploratory, and intuitive research environment for scientists on both sides. Additional updates pertaining to the Bayer partnership include: We initiated our first joint oncology project which is now expected to advance rapidly towards Lead Series nomination; and We are on track to complete 25 unique multi-modal data packages that we expect to deliver in the third quarter of 2024. Platform updates ADME industrialization: potential to achieve an estimated 90 times the amount of lab throughput over a manual approach. Built our first genome-scale transcriptomics knockout map. Multimodal mapping has enabled us in certain experiments to achieve 90% success on our ability to predict compounds that failed later disease-relevant assays in internal tests and 60% ability to predict compounds that passed later disease-relevant assays in internal tests. Helix partnership brings hundreds of thousands of unique de-identified patient records across diverse therapeutic areas.